{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:35:11Z","timestamp":1792499711145,"version":"4.5.0"},"reference-count":39,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp;amp; Translational Med"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mutations in the <jats:italic>AT\u2010rich interactive domain\u2010containing protein 1A (ARID1A)<\/jats:italic> gene are frequently found in pancreatic cancer. However, the contribution of ARID1A inactivation to pancreatic tumorigenesis remains unclear. Previous work showed that depletion of Arid1a at early developmental stages induces metabolic disturbance and diabetes mellitus in mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>In this study, we generated a genetically engineered mouse model harboring both <jats:italic>K\u2010ras<\/jats:italic> mutation and <jats:italic>Arid1a<\/jats:italic> depletion (KAR mice). We found that the combination of these two genetic alterations induces pancreatic tumor formation. Compared to tumors in <jats:italic>K\u2010ras<\/jats:italic> and <jats:italic>Tp53<\/jats:italic>\u2010mutant mice (KPC mice), KAR tumors showed increased immune cell infiltration and reduced stromal activation. Transcriptomic analysis revealed significant upregulation of fatty acid metabolism and <jats:italic>fatty acid synthase (FASN)<\/jats:italic> in KAR tumors, with ARID1A directly regulating <jats:italic>Fasn<\/jats:italic> expression. Pharmacological inhibition of FASN reduced tumor cell viability and slowed tumor progression in vivo. Analysis of clinical datasets showed an inverse correlation between ARID1A and FASN expression, with high FASN levels predicting worse patient survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ARID1A deficiency promotes fatty acid metabolism to accelerate pancreatic tumorigenesis. FASN is a potential therapeutic target for ARID1A\u2010deficient pancreatic cancer.Mutations in AT\u2010rich interactive domain\u2010containing protein 1A (<jats:italic>ARID1A<\/jats:italic>) gene are frequently found in pancreatic cancer. However, the contribution of ARID1A inactivation to pancreatic tumourigenesis is not well\u2010characterised. Previously, we generated genetically engineered mice with specific depletion of <jats:italic>Arid1a<\/jats:italic> gene in the pancreas and found that depletion of <jats:italic>Arid1a<\/jats:italic> at early developmental stage induced metabolic disturbance and diabetes mellitus. In this study, we established a mouse model with <jats:italic>K\u2010ras<\/jats:italic> mutation and <jats:italic>Arid1a<\/jats:italic> depletion (KAR mice) in the pancreas and showed that the combination of these two genetic alterations induced pancreatic tumour formation. Compared to the tumours developed in mice with <jats:italic>K\u2010ras<\/jats:italic> mutation and <jats:italic>Tp53<\/jats:italic> deficiency (KPC mice), KAR tumours exhibited increased immune cell infiltration and reduced stromal activation. Our results demonstrated a significant upregulation of fatty acid metabolism and fatty acid synthase (FASN) in the KAR tumours, with ARID1A directly regulating <jats:italic>FASN<\/jats:italic> expression. Inhibition of FASN by chemical inhibitor reduced tumour cell viability and slowed tumour progression in mice. Clinical data revealed a negative correlation between ARID1A expression and FASN, with high FASN levels associated with worse patient survival. Collectively, ARID1A deficiency upregulates fatty acid metabolism to accelerate pancreatic tumourigenesis and FASN is a potential therapeutic target for ARID1A\u2010deficient pancreatic cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key points<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>ARID1A mutations drive metabolic reprogramming in pancreatic cancer.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Co\u2010occurrence of K\u2010ras mutation and Arid1a loss induces tumor formation with distinct immune microenvironment features.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>FASN is upregulated by ARID1A deficiency and its inhibition suppresses tumor growth.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Targeting FASN may benefit patients with ARID1A\u2010deficient pancreatic cancer.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/ctm2.70394","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T05:10:19Z","timestamp":1751865019000},"source":"Crossref","is-referenced-by-count":5,"title":["Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1650-493X","authenticated-orcid":false,"given":"Tzu\u2010Lei","family":"Kuo","sequence":"first","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Chin","family":"Hou","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, School of Medicine, National Cheng Kung University  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-5189","authenticated-orcid":false,"given":"Yan\u2010Shen","family":"Shan","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine, School of Medicine, National Cheng Kung University  Tainan Taiwan"},{"name":"Department of Surgery National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-7167","authenticated-orcid":false,"given":"Li\u2010Tzong","family":"Chen","sequence":"additional","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes  Tainan Taiwan"},{"name":"Division of Hematology &amp; Oncology, Department of Internal Medicine Kaohsiung Medical University Hospital  Kaohsiung Taiwan"},{"name":"Faculty of Medicine College of Medicine, Kaohsiung Medical University  Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4860-5415","authenticated-orcid":false,"given":"Wen\u2010Chun","family":"Hung","sequence":"additional","affiliation":[{"name":"National Institute of Cancer Research, National Health Research Institutes  Tainan Taiwan"},{"name":"Department of Pharmacy College of Pharmacy, Kaohsiung Medical University  Kaohsiung Taiwan"},{"name":"Department of Biological Science and Technology National Yang Ming Chiao Tung University  Hsinchu Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010491"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11547"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14169"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0361"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2018.04.003"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3582"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053931"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.17.2117"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2522"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0541-5"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.03.039"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315541"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315490"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092695"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105881"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111581"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0858-1"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2016.08.011"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0849"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13837"},{"key":"e_1_2_10_26_1","first-page":"5952","article-title":"Targeting the alterations of ARID1A in pancreatic cancer: tumorigenesis, prediction of treatment, and prognostic value","volume":"14","author":"Li R","year":"2022","journal-title":"Am J Transl Res"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.155899"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.21306"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40661-017-0052-y"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-19459-z"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.899987"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.102128"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25361"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617709114"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210033"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M039347"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc4220"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2404"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150453"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.7150\/thno.28201"}],"container-title":["Clinical and Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ctm2.70394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T06:50:43Z","timestamp":1755845443000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ctm2.70394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/ctm2.70394"],"URL":"https:\/\/doi.org\/10.1002\/ctm2.70394","archive":["Portico"],"relation":{},"ISSN":["2001-1326","2001-1326"],"issn-type":[{"value":"2001-1326","type":"print"},{"value":"2001-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"e70394"}}